Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 29681 results found since Jan 2013.
Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer
Clin Exp Immunol. 2023 Sep 11:uxad105. doi: 10.1093/cei/uxad105. Online ahead of print.ABSTRACTChemo-immunotherapy has become the best first-line treatment for advanced lung cancer patients without oncogenic drivers. However, it may also lead to an increased incidence and severity of treatment-related adverse events. In this retrospective study, lung cancer patients administrated with either anti-PD-1 or anti-PD-L1 treatment plus chemotherapy were included. Data on demographic characteristics, disease characteristics, treatment strategies, laboratory results and clinical outcomes were collected from the Electronic Medical ...
Source: Clinical and Developmental Immunology - September 11, 2023 Category: Allergy & Immunology Authors: Jinjin Li Wenhao Shi Jin Xiong Yusheng Huang Yi He Yan Zhou Zhenzhou Yang Yuan Peng Source Type: research
Biomarkers to guide immunomodulatory treatment: where do we stand?
Expert Rev Mol Diagn. 2023 Sep 10. doi: 10.1080/14737159.2023.2258063. Online ahead of print.ABSTRACTINTRODUCTION: This review summarizes current progress in the development of biomarkers to guide immunotherapy in oncology, rheumatology and critical illness.AREAS COVERED: An extensive literature search was performed about biomarkers classifying patients' immune responses to guide immunotherapy in oncology, rheumatology and critical illness. Surface markers, such as programmed death-ligand 1 (PD-L1), genetic biomarkers, such as tumor mutation load, and circulating tumor DNA are biomarkers associated with the effectiveness o...
Source: Expert Review of Molecular Diagnostics - September 11, 2023 Category: Laboratory Medicine Authors: Evdoxia Kyriazopoulou Evangelos J Giamarellos-Bourboulis Karolina Akinosoglou Source Type: research
Potential association of HSPD1 with dysregulations in ribosome biogenesis and immune cell infiltration in lung adenocarcinoma: An integrated bioinformatic approach
CONCLUSIONS: HSPD1 may play a role in the regulation of ribosome biogenesis and B cell-mediated immunity in LUAD. It could serve as a predictive biomarker for prognosis and immunotherapy response in LUAD.PMID:37694354 | DOI:10.3233/CBM-220442
Source: Cancer Biomarkers : Section A of Disease Markers - September 11, 2023 Category: Cancer & Oncology Authors: Siripat Aluksanasuwan Keerakarn Somsuan Jatuporn Ngoenkam Somchai Chutipongtanate Sutatip Pongcharoen Source Type: research
Microbiota-dependent regulation of costimulatory and coinhibitory pathways via innate immune sensors and implications for immunotherapy
Exp Mol Med. 2023 Sep 11. doi: 10.1038/s12276-023-01075-0. Online ahead of print.ABSTRACTOur bodies are inhabited by trillions of microorganisms. The host immune system constantly interacts with the microbiota in barrier organs, including the intestines. Over decades, numerous studies have shown that our mucosal immune system is dynamically shaped by a variety of microbiota-derived signals. Elucidating the mediators of these interactions is an important step for understanding how the microbiota is linked to mucosal immune homeostasis and gut-associated diseases. Interestingly, the efficacy of cancer immunotherapies that ma...
Source: Molecular Medicine - September 11, 2023 Category: Molecular Biology Authors: Joon Seok Park Francesca S Gazzaniga Dennis L Kasper Arlene H Sharpe Source Type: research
Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer
Clin Exp Immunol. 2023 Sep 11:uxad105. doi: 10.1093/cei/uxad105. Online ahead of print.ABSTRACTChemo-immunotherapy has become the best first-line treatment for advanced lung cancer patients without oncogenic drivers. However, it may also lead to an increased incidence and severity of treatment-related adverse events. In this retrospective study, lung cancer patients administrated with either anti-PD-1 or anti-PD-L1 treatment plus chemotherapy were included. Data on demographic characteristics, disease characteristics, treatment strategies, laboratory results and clinical outcomes were collected from the Electronic Medical ...
Source: Clinical and Developmental Immunology - September 11, 2023 Category: Allergy & Immunology Authors: Jinjin Li Wenhao Shi Jin Xiong Yusheng Huang Yi He Yan Zhou Zhenzhou Yang Yuan Peng Source Type: research
Comprehensive profiling of enhancer RNA in stage II/III colorectal cancer defines two prognostic subtypes with implications for immunotherapy
CONCLUSION: Our study unravels the molecular heterogeneity of stage II/III CRC at the eRNA level and highlights the potential applications of the novel eRNA-based subtyping system in predicting prognosis and guiding immunotherapy.PMID:37697139 | DOI:10.1007/s12094-023-03319-x
Source: Clinical Colorectal Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Xiaoyun Bu Shuang Liu Zhiqing Zhang Jie Wu Shuguang Pan Yingbin Hu Source Type: research
Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy
Biochim Biophys Acta Mol Basis Dis. 2023 Sep 9:166881. doi: 10.1016/j.bbadis.2023.166881. Online ahead of print.ABSTRACTGastric cancer (GC) is an increasing global health problem and is one of the leading cancers worldwide. Traditional therapies, such as radiation and chemotherapy, have made limited progress in enhancing their efficacy for advanced GC. The development of immunotherapy for advanced GC has considerably improved with a deeper understanding of the tumor microenvironment. Immunotherapy using checkpoint inhibitors is a new therapeutic option that has made substantial advances in the treatment of other malignanci...
Source: Biochimica et Biophysica Acta - September 11, 2023 Category: Biochemistry Authors: Xianzhe Yu Xiaoqian Zhai Juan Wu Qingbo Feng Chenggong Hu Lingling Zhu Qinghua Zhou Source Type: research
Biomarkers to guide immunomodulatory treatment: where do we stand?
Expert Rev Mol Diagn. 2023 Sep 10. doi: 10.1080/14737159.2023.2258063. Online ahead of print.ABSTRACTINTRODUCTION: This review summarizes current progress in the development of biomarkers to guide immunotherapy in oncology, rheumatology and critical illness.AREAS COVERED: An extensive literature search was performed about biomarkers classifying patients' immune responses to guide immunotherapy in oncology, rheumatology and critical illness. Surface markers, such as programmed death-ligand 1 (PD-L1), genetic biomarkers, such as tumor mutation load, and circulating tumor DNA are biomarkers associated with the effectiveness o...
Source: Expert Review of Molecular Diagnostics - September 11, 2023 Category: Laboratory Medicine Authors: Evdoxia Kyriazopoulou Evangelos J Giamarellos-Bourboulis Karolina Akinosoglou Source Type: research
Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy
Biochim Biophys Acta Mol Basis Dis. 2023 Sep 9:166881. doi: 10.1016/j.bbadis.2023.166881. Online ahead of print.ABSTRACTGastric cancer (GC) is an increasing global health problem and is one of the leading cancers worldwide. Traditional therapies, such as radiation and chemotherapy, have made limited progress in enhancing their efficacy for advanced GC. The development of immunotherapy for advanced GC has considerably improved with a deeper understanding of the tumor microenvironment. Immunotherapy using checkpoint inhibitors is a new therapeutic option that has made substantial advances in the treatment of other malignanci...
Source: Biochimica et Biophysica Acta - September 11, 2023 Category: Biochemistry Authors: Xianzhe Yu Xiaoqian Zhai Juan Wu Qingbo Feng Chenggong Hu Lingling Zhu Qinghua Zhou Source Type: research
Inhibiting autophagy to boost antitumor immunity with tetramethylpyrazine-loaded and PD-L1-targeting Liposomal Nanoparticles
Eur J Pharm Sci. 2023 Sep 9:106581. doi: 10.1016/j.ejps.2023.106581. Online ahead of print.ABSTRACTCancer immunotherapy has been recognized as a revolutionary breakthrough and has yielded impressive results. However, a major challenge facing immunotherapy is its limited efficacy, which may be largely due to the inadequate infiltration of immune cells into the tumor microenvironment (TME). Autophagy inhibition has been identified to enhance the recruitment of immune cells into the tumor by upregulating the expression and secretion of chemokines. Here, we verified a novel autophagy inhibitor tetramethylpyrazine (TMP) from na...
Source: European Journal of Pharmaceutical Sciences - September 11, 2023 Category: Drugs & Pharmacology Authors: Fei Zhou Xiaojiaoyang Li Kexin Jia Fanghong Li Xiaoyong Xue Jia Liu Jiaorong Qu Runping Liu Source Type: research
Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer
Clin Exp Immunol. 2023 Sep 11:uxad105. doi: 10.1093/cei/uxad105. Online ahead of print.ABSTRACTChemo-immunotherapy has become the best first-line treatment for advanced lung cancer patients without oncogenic drivers. However, it may also lead to an increased incidence and severity of treatment-related adverse events. In this retrospective study, lung cancer patients administrated with either anti-PD-1 or anti-PD-L1 treatment plus chemotherapy were included. Data on demographic characteristics, disease characteristics, treatment strategies, laboratory results and clinical outcomes were collected from the Electronic Medical ...
Source: Clinical Lung Cancer - September 11, 2023 Category: Cancer & Oncology Authors: Jinjin Li Wenhao Shi Jin Xiong Yusheng Huang Yi He Yan Zhou Zhenzhou Yang Yuan Peng Source Type: research
CD160 Signaling Is Essential for CD8+ T Cell Memory Formation via Upregulation of 4-1BB
J Immunol. 2023 Sep 11:ji2200792. doi: 10.4049/jimmunol.2200792. Online ahead of print.ABSTRACTA better understanding of the regulatory mechanisms governing the development of memory CD8+ T cells could provide instructive insights into vaccination strategies and T cell-based immunotherapies. In this article, we showed that CD160 surface protein is required for CD8+ T cell memory formation. In the response to acute lymphocytic choriomeningitis virus infection in a mouse model, CD160 ablation resulted in the failure of the development of all three memory CD8+ T cell subsets (central, effective, and tissue-resident memory), c...
Source: Journal of Immunology - September 11, 2023 Category: Allergy & Immunology Authors: Linxia Zhang Anli Zhang Xinyu Zhu Xinmei Tian Jiaohan Guo Qian He Lingyan Zhu Songhua Yuan Chen Zhao Xiaoyan Zhang Jianqing Xu Source Type: research
Potential association of HSPD1 with dysregulations in ribosome biogenesis and immune cell infiltration in lung adenocarcinoma: An integrated bioinformatic approach
CONCLUSIONS: HSPD1 may play a role in the regulation of ribosome biogenesis and B cell-mediated immunity in LUAD. It could serve as a predictive biomarker for prognosis and immunotherapy response in LUAD.PMID:37694354 | DOI:10.3233/CBM-220442
Source: Cancer Biomarkers : Section A of Disease Markers - September 11, 2023 Category: Cancer & Oncology Authors: Siripat Aluksanasuwan Keerakarn Somsuan Jatuporn Ngoenkam Somchai Chutipongtanate Sutatip Pongcharoen Source Type: research
